Economic and clinical impact of multiple myeloma to managed care

Journal of Managed Care Pharmacy

Volumn 14, Issue 7 SUPPL., 2008, Pages

  Cook, Richard ^a  

^a Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; PROTEASOME INHIBITOR; STEROID; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ANEMIA; BLOOD TRANSFUSION; BONE DISEASE; BONE LESION; BONE PAIN; CANCER MORTALITY; CANCER RISK; CAREGIVER; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ECONOMIC ASPECT; FRACTURE; GENE MUTATION; HEALTH CARE PLANNING; HEALTH INSURANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY FAILURE; LENGTH OF STAY; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MANAGED CARE; MORBIDITY; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SOCIAL SUPPORT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 54449087372     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.s7-a.19     Document Type: Review

References (25)

1. National Cancer Institute. Cancer Trends Progress Report-2007 Update. Available at: http://progressreport.cancer.gov/ doc_detail.asp?pid=l&did=200 7&chid=75&coid=726&mid. Accessed on March 26, 2008.
2. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109:2334-42.
3. American Cancer Society. Costs of Cancer. Available at: www.cancer.org/ docroot/MIT/content/MIT_3_2X_costs_of_cancer.asp. Accessed July 22, 2008.
4. Cancer Facts and Figures 2008. CA Cancer J Clin. 2008;58:71-96. Available at: www.cancer.org/docroot/STT/content/ STT_1x_Cancer_Facts_and_Figures_2008.asp?from=fast. Accessed March 24, 2008.
5. Leukemia & Lymphoma Society. Myeloma Facts & Statistics. Available at: www.leukemia-lymphoma.org/ all_page?item_id=6989&vie. Accessed March 25, 2008.
6. The NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology (Version 1.2008) 2007 National Comprehensive Cancer Network, Inc. Available at: www.nccn.org. Accessed March 19, 2008. To view the most recent and complete version of the guideline, go online to: www.nccn.org.
7. Cook R. An economic perspective on treatment options in multiple myeloma. Managed Care Oncol. Spring 2007;3:10-12.
8. Lederman L. International Myeloma Foundation. ASCO 2007 Highlights for Physicians. Available at: http://myeloma.org/ main.jsp?source=link&source_link_id= 2803&type=article&tab_id=8&menu_id=0&id=2183. Accessed March 7, 2008.
9. Porter CA, Rifkin RM. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma. 2007;7(Suppl 4):S150-S155.
10. Jones JA, Qazilbash MH, Shih YT, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer. 2008;112:1096-105.
11. Meehan KR, Fitzmaurice T, Root L, Kimtis E, Patchett L, Hill J. The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients. J Support Oncol. 2006;4:187-90.
12. Djulbegovic B, Kumar A. Multiple myeloma: detecting the effects of new treatments. Lancet. 2008;371:1642-44.
13. Schwartzberg L. Managed care considerations in the treatment of multiple myeloma. Managed Care Oncol. Spring 2007;3:14-16, 47.
14. Fullerton DS, Hulehatt H, Huang H., et al. ASH 2007 Annual Meeting, Atlanta, GA; Dec 8-11, 2007.
15. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:717-41.
16. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol. 2005;28:8-16.
17. McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics. 2008;26:251-68.
18. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol. 1998;16:1218-25.
19. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007; 25:2464-72.
20. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620-3.
21. Coyte PC, Dobrow MJ, Broadfield L. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics. 2001;19:845-54.
22. Saad F, Lipton A, Cook R, et al. Pathological fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860-67.
23. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-505.
24. Academy of Managed Care Pharmacy. Concepts in Managed Care Pharmacy: Outcomes Research. Available at: www.amcp.org/amcp.ark?p=AAAC630C. Accessed March 25, 2008.
25. Foundation for Managed Care Pharmacy Inc. The Value of Pharmaceuticals and Managed Pharmaceutical Care. 2001. Available at: www.amcp.org/amcp.ark?pl=ADABEA19. Accessed March 19, 2008.